("OKYO" or the "Company") - OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain
28 avr. 2021 02h00 HE
|
OKYO Pharma LTD
LONDON and BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO announces appointment of Dr Rajkumar Patil as Chief Scientific Officer
29 mars 2021 02h00 HE
|
OKYO Pharma LTD
LONDON, March 29, 2021 (GLOBE NEWSWIRE) -- OKYO (LSE: OKYO; OTCQB: EMMLF), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited ("OKYO" or the "Company") - Issue of Equity
01 mars 2021 02h00 HE
|
OKYO Pharma LTD
LONDON, March 01, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ("OKYO" or the "Company") today announces that it has issued 250,000 ordinary shares of no par value ("Ordinary Shares"), credited as...
OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation
23 févr. 2021 02h00 HE
|
OKYO Pharma LTD
LONDON, Feb. 23, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ("OKYO" or the "Company"), a biotechnology company focused on the development of novel drugs to treat inflammatory eye diseases and...
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat “cytokine storm” associated with COVID-19 and ARDS
19 janv. 2021 02h00 HE
|
OKYO Pharma LTD
LONDON and BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- OKYO (LSE: OKYO; OTCQB: EMMLF), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited ("OKYO" or the "Company") - Result of the Annual General Meeting
25 sept. 2020 07h00 HE
|
OKYO Pharma LTD
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM...
Notice of Annual General Meeting
09 sept. 2020 02h00 HE
|
OKYO Pharma LTD
LONDON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited ("OKYO" or the "Company") - Appointment of Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board
19 août 2020 02h00 HE
|
OKYO Pharma LTD
LONDON, Aug. 19, 2020 (GLOBE NEWSWIRE) -- OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and...
OKYO Pharma Limited ("OKYO" or the "Company") - Issue of additional convertible loan notes to raise £1,437,104 and intention to seek dual listing on NASDAQ
18 août 2020 02h00 HE
|
OKYO Pharma LTD
LONDON, Aug. 18, 2020 (GLOBE NEWSWIRE) -- OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and...
Dr James Khodabakhsh MD named Chairman of the Scientific Advisory Board at OKYO Pharma Ltd
07 août 2020 02h00 HE
|
OKYO Pharma LTD
LONDON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- OKYO (LSE:OKYO), the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye...